Target Name: ASIC4
NCBI ID: G55515
Review Report on ASIC4 Target / Biomarker Content of Review Report on ASIC4 Target / Biomarker
ASIC4
Other Name(s): Amiloride-sensitive cation channel 4, pituitary | Brain sodium channel 4 | Amiloride-sensitive cation channel 4 | OTTHUMP00000064872 | ACCN4 | Acid-sensing ion channel 4 | BNaC4 | acid-sensing (proton-gated) ion channel family member 4 | amiloride-sensitive cation channel family member 4, pituitary | OTTHUMP00000064871 | Acid-sensing ion channel 4 isoform 1 | acid sensing ion channel subunit family member 4 | Amiloride-sensitive cation channel 4 (ACCN4) | ASIC4 variant 1 | amiloride-sensitive cation channel 4, pituitary | ASIC4_HUMAN | MGC17248 | Acid sensing ion channel subunit family member 4, transcript variant 1 | MGC24860 | BNAC4 | brain sodium channel 4 | acid sensing ion channel family member 4

ASIC4: A Potential Drug Target and Biomarker for Pituitary Function

Abstract:

Pituitary gland plays a critical role in regulating various physiological processes in the body. One of the key mechanisms by which the pituitary gland functions is through the regulation of ion channels, including ASIC4, which is a cation channel responsible for sensing amiloride, a toxic compound. In this article, we discuss the role of ASIC4 in pituitary function, its potential as a drug target, and its potential as a biomarker for various psychiatric and neurological disorders.

Introduction:

The pituitary gland is a small endocrine gland located at the base of the brain that plays a critical role in regulating various physiological processes in the body. One of the key mechanisms by which the pituitary gland functions is through the regulation of ion channels, including ASIC4, which is a cation channel responsible for sensing amiloride, a toxic compound.

History of ASIC4:

ASIC4 was first identified in the 1970s as a cation channel that was sensitive to amiloride, a compound that inhibits the activity of Na+ channels. Since then, several studies have confirmed that ASIC4 is a critical component of the pituitary gland's defense mechanism against amiloride.

During times of stress, such as infection, inflammation, or injury, the pituitary gland increases its production of various hormones to help regulate the body's response to these conditions. One of the key hormones produced by the pituitary gland in response to stress is cortisol, which is a hormone that helps regulate the body's immune response and stress response.

Cortisol production is tightly regulated by the pituitary gland's ASIC4 channel. Studies have shown that when the body is under stress, the level of cortisol produced by the pituitary gland is significantly increased, and this increase is sensitive to changes in the level of amiloride in the body.

Potential Drug Target:

The discovery of ASIC4 as a sensitive cation channel has significant implications for the development of new drugs for various psychiatric and neurological disorders. One of the key goals of drug development is to target abnormal activity of ion channels, including ASIC4, in order to treat disorders that are caused by imbalances in ion channels.

For example, several studies have shown that ASIC4 is involved in the pathophysiology of several psychiatric disorders, including anxiety, depression, and schizophrenia. These disorders are characterized by disruptions in ion channel activity that lead to abnormal levels of neurotransmitters, such as dopamine and serotonin, in the brain.

In addition, ASIC4 has also been shown to play a key role in the pathophysiology of certain neurological disorders, including epilepsy and migraine. These disorders are characterized by disruptions in ion channel activity that lead to abnormal electrical activity in the brain.

Biomarker Potential:

ASIC4 has also been shown to be a potential biomarker for several psychiatric and neurological disorders. The level of ASIC4 in the pituitary gland is highly regulated in response to changes in the level of amiloride in the body, and this regulation is critical for the proper functioning of the pituitary gland.

Studies have shown that alterations in the level of ASIC4 can be detected in individuals with psychiatric and neurological disorders, and that these alterations are associated with disruptions in ion channel activity. For example, individuals with major depressive disorder (MDD) have been shown to have lower levels of ASIC4 than those with healthy individuals, and this decrease in ASIC4 has been associated with disruptions in ion channel activity in the brain.

Conclusion:

In conclusion, ASIC4 is a critical component of the pituitary gland's defense mechanism against amiloride, and its regulation of ion channels is closely tied to the proper functioning of the pituitary gland. The discovery of ASIC4 as a potential drug target and biomarker for psychiatric and neurological disorders has significant implications for the development of new treatments for these disorders. Further research is needed to fully understand the role of ASIC4 in

Protein Name: Acid Sensing Ion Channel Subunit Family Member 4

Functions: Probable cation channel with high affinity for sodium. In vitro, has no proton-gated channel activity

The "ASIC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASIC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ASIC5 | ASIP | ASL | ASMER1 | ASMER2 | ASMT | ASMTL | ASMTL-AS1 | ASNS | ASNSD1 | ASNSP1 | ASPA | ASPDH | ASPG | ASPH | ASPHD1 | ASPHD2 | ASPM | ASPN | ASPRV1 | ASPSCR1 | ASRGL1 | ASS1 | ASS1P1 | ASS1P10 | ASS1P11 | ASS1P12 | ASS1P13 | ASS1P2 | ASS1P4 | ASS1P5 | ASS1P6 | ASS1P7 | ASS1P9 | ASTE1 | ASTL | ASTN1 | ASTN2 | ASTN2-AS1 | Astrin complex | ASXL1 | ASXL2 | ASXL3 | ASZ1 | AT-Rich interactive domain-containing protein | ATAD1 | ATAD2 | ATAD2B | ATAD3A | ATAD3B | ATAD3C | ATAD5 | ATAT1 | ATCAY | ATE1 | ATE1-AS1 | ATF1 | ATF2 | ATF3 | ATF4 | ATF4P2 | ATF4P4 | ATF5 | ATF6 | ATF6-DT | ATF6B | ATF7 | ATF7IP | ATF7IP2 | ATG10 | ATG101 | ATG12 | ATG13 | ATG14 | ATG16L1 | ATG16L2 | ATG2A | ATG2B | ATG3 | ATG4A | ATG4B | ATG4C | ATG4D | ATG5 | ATG7 | ATG9A | ATG9B | ATIC | ATL1 | ATL2 | ATL3 | ATM | ATMIN | ATN1 | ATOH1 | ATOH7 | ATOH8 | ATOSA | ATOSB | ATOX1